[go: up one dir, main page]

NO974076L - Reduksjon av infarktvolum ved å anvende citicolin - Google Patents

Reduksjon av infarktvolum ved å anvende citicolin

Info

Publication number
NO974076L
NO974076L NO974076A NO974076A NO974076L NO 974076 L NO974076 L NO 974076L NO 974076 A NO974076 A NO 974076A NO 974076 A NO974076 A NO 974076A NO 974076 L NO974076 L NO 974076L
Authority
NO
Norway
Prior art keywords
citicoline
reduction
treatment
infarct volume
infarction
Prior art date
Application number
NO974076A
Other languages
English (en)
Other versions
NO974076D0 (no
NO313538B1 (no
Inventor
Bobby Winston Sandage
Marc Fisher
Kenneth W Locke
Original Assignee
Interneuron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974076(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/603,102 external-priority patent/US5872108A/en
Priority claimed from US08/609,448 external-priority patent/US5827832A/en
Application filed by Interneuron Pharma filed Critical Interneuron Pharma
Publication of NO974076D0 publication Critical patent/NO974076D0/no
Publication of NO974076L publication Critical patent/NO974076L/no
Publication of NO313538B1 publication Critical patent/NO313538B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
NO19974076A 1995-03-06 1997-09-04 Anvendelse av citicolin samt farmasöytisk preparat NO313538B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39926295A 1995-03-06 1995-03-06
US08/603,102 US5872108A (en) 1995-03-06 1996-02-20 Reduction of infarct volume using citicoline
US08/609,448 US5827832A (en) 1995-03-06 1996-03-01 Method of protecting brain tissue from cerebral infarction subsequent to ischemia
PCT/US1996/003159 WO1996027380A1 (en) 1995-03-06 1996-03-06 Reduction of infarct volume using citicoline

Publications (3)

Publication Number Publication Date
NO974076D0 NO974076D0 (no) 1997-09-04
NO974076L true NO974076L (no) 1997-10-28
NO313538B1 NO313538B1 (no) 2002-10-21

Family

ID=27410335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974076A NO313538B1 (no) 1995-03-06 1997-09-04 Anvendelse av citicolin samt farmasöytisk preparat

Country Status (14)

Country Link
EP (1) EP0813416B1 (no)
JP (1) JPH11511732A (no)
CN (2) CN1126546C (no)
AT (1) ATE296103T1 (no)
AU (1) AU5304796A (no)
BR (1) BR9607206A (no)
CA (1) CA2213000A1 (no)
DE (1) DE69634773T2 (no)
ES (1) ES2244968T3 (no)
MX (1) MX9706808A (no)
NO (1) NO313538B1 (no)
PL (1) PL185124B1 (no)
PT (1) PT813416E (no)
WO (1) WO1996027380A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
AU1944799A (en) * 1997-12-24 1999-07-19 Interneuron Pharmaceuticals, Inc. Hyperhydrated citicoline, process and use
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
ES2169986B1 (es) * 2000-03-14 2003-06-16 Ferrer Int Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
HUP0402332A3 (en) 2001-10-15 2009-07-28 Janssen Pharmaceutica Nv Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage and pharmaceutical compositions containing them
AU2003299715A1 (en) * 2002-12-20 2004-07-22 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
AU2013268725B2 (en) 2012-05-31 2017-02-16 Asahi Kasei Pharma Corporation Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
NZ707081A (en) * 2012-10-30 2019-03-29 Kyowa Hakko Bio Co Ltd Agent for preventing or improving decline in brain function
CN105769882B (zh) * 2016-03-14 2019-02-22 北京赛德维康医药研究院 一种抑制血栓形成的药物组合物及其用途
KR102442669B1 (ko) 2017-05-09 2022-09-13 호스피탈 크리닉 드 바르셀로나 기계적 혈전제거술로써 치료된 뇌졸중 환자의 치료를 위한 요산을 포함하는 조성물
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
IT1207106B (it) * 1980-04-18 1989-05-17 Made Italiana Srl Ora Searle I Preparazione farmaceutica contenente citidin disfofocolina assorbibile per via orale

Also Published As

Publication number Publication date
ATE296103T1 (de) 2005-06-15
PT813416E (pt) 2005-10-31
BR9607206A (pt) 1997-11-11
NO974076D0 (no) 1997-09-04
CN1488353A (zh) 2004-04-14
CN1181015A (zh) 1998-05-06
MX9706808A (es) 1998-08-30
EP0813416A4 (en) 2000-11-15
ES2244968T3 (es) 2005-12-16
NO313538B1 (no) 2002-10-21
PL322061A1 (en) 1998-01-05
JPH11511732A (ja) 1999-10-12
EP0813416B1 (en) 2005-05-25
DE69634773T2 (de) 2006-05-04
DE69634773D1 (de) 2005-06-30
CA2213000A1 (en) 1996-09-12
AU5304796A (en) 1996-09-23
EP0813416A1 (en) 1997-12-29
PL185124B1 (pl) 2003-02-28
WO1996027380A1 (en) 1996-09-12
CN1126546C (zh) 2003-11-05

Similar Documents

Publication Publication Date Title
NO974076D0 (no) Reduksjon av infarktvolum ved å anvende citicolin
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
GR3007251T3 (no)
EP0703785B8 (en) Methods for treating muscle diseases and disorders
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BG97068A (bg) Фармацевтичен състав и метод за постигане на терапевтичен ефект
EP0945135A3 (en) Treatment of alzheimer's disease and modulation of immune system with Delta5-Androstenes
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
KR950701223A (ko) 항허혈성(Anti-ichemic)약물
AU4385399A (en) Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
EP1294375A4 (en) METHOD FOR THE TREATMENT OF SEBORRHOIC DERMATITIS
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
SE9302333D0 (sv) New compounds
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
NZ299006A (en) Use of 4-dichlorophenyl tetrahydro N-methyl-1-naphthalenamine (sertraline) for heart attack treatment
Almeida et al. Effects of a purified scorpion toxin (tityustoxin) on the isolated guinea pig heart
ES2194907T3 (es) Utilizacion de la espiramicina en desordenes gastro-intestinales debido al h.pylori.
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
MX9602793A (es) Uso de sertralina para tratar pacientes despues de un infarto de miocardio.

Legal Events

Date Code Title Description
MK1K Patent expired